Pharma · · 8 min read
How to evaluate agentic AI for pharma commercial teams
Acumen Editorial · Updated November 20, 2026
Agentic AI has moved from pilots into the commercial stack. In a November 5, 2026 PMLiVE piece, Veeva's Chris Moore described agents that write call reports, answer HCP questions on digital channels and review promotional content against approved labels and claim libraries. IQVIA markets four families of commercial agents, from market insights to field engagement.
The pitch is speed. The risk is that an agent now drafts, recommends and answers in a regulated channel, at volume, before a human sees every output. That changes what evaluation has to prove.
If you lead commercial AI, omnichannel, brand operations or MLR at a pharma company, here is how we would test these agents before they reach the field.
What does agentic AI actually do in pharma commercial?
Vendors describe a fairly consistent set of jobs. Based on Veeva's January 2026 product blog and its November 2026 PMLiVE article, plus IQVIA's commercial agentic AI page, the common agents are:
- Pre-call and planning agents that build engagement plans and talking points from call notes and signals such as conference attendance.
- Call report agents that turn dictated notes into structured reports and flag compliance issues, such as patient names in free text.
- Conversational agents on HCP and patient channels that, per Veeva, answer only from MLR-approved content.
- Content and MLR agents that pre-check drafts for issues like overstated efficacy and summarize material for medical, legal and regulatory reviewers.
- Insight and planning agents that combine sales, prescription, CRM and digital data into forecasts and market views.
Each job fails differently. A planning agent that misreads a prescriber wastes a call. A conversational agent that drifts off-label creates a promotional violation. One test score cannot cover both.
Why aren't vendor accuracy numbers enough?
Vendor numbers are a starting point, not evidence. IQVIA's commercial agentic AI page cites 97% accuracy for agent outputs in production tests but does not describe how it was measured. Veeva's PMLiVE article reports a 7x lift in high-value actions from conversational AI and says 65% of agentic call reports identify actionable treatment barriers. Both are vendor-reported.
None of these numbers tell you how an agent performs on your brand, your label and your therapy area. They also rarely say who graded the outputs. "Accurate" judged by a generalist annotator is not the same as accurate judged by a promotional review specialist who knows fair balance.
Buyers know this. In a Veeva PromoMats survey of 101 content professionals across 10 biopharmas, published April 2026, 48% flagged areas that need attention, including output accuracy and reliability, auditability and human oversight.
The data underneath is also a known weak point. Veeva's own research found 96% of leaders say their data is not well structured or AI-ready.
What does FDA enforcement tell you to test?
FDA has not issued guidance on AI in drug advertising. At a RAPS conference in March 2026, former OPDP project manager Jason Cober said companies "kind of have to make inferences about what the agency is thinking." FDA's January 2025 draft guidance on AI in drug development does not address promotion.
The rules on the content itself have not changed, and enforcement shows where outputs go wrong. Covington's November 11, 2026 enforcement update counts five OPDP untitled letters posted in Q3 2026. The themes map cleanly to agent tests:
| OPDP theme (Q3 2026) | Where an agent could repeat it | What to test |
|---|---|---|
| Overstated efficacy | Content drafts, conversational answers | Claims checked against label and claims library |
| Exploratory data presented as proof | Talking points, objection responses | Endpoint and subgroup framing |
| Omitted or minimized risk | Short-form answers, emails, social copy | Fair balance in every format and length |
| Overly broad indication references | HCP emails, pre-call plans | Indication wording matched to the label |
| Promotion of investigational products | Pipeline questions from HCPs | Refusal or redirect to medical information |
Covington notes two of the letters involved an Instagram post and professional emails to HCPs. Those are exactly the short, high-volume formats agents are built to produce.
How should you build the evaluation set?
Build it privately and build it from your own material. Public benchmarks do not know your label. Here is the checklist we use:
- Scope one agent at a time. Write down its job, its allowed sources and what it must never do.
- Write realistic inputs. Real HCP objections by specialty, payer questions, messy dictated call notes and off-label requests phrased the way people ask them.
- Include adversarial cases. Pipeline questions, comparative claims, dosing outside label and requests for patient-identifying detail.
- Write reference answers and rubrics. Score on-label accuracy, fair balance, data accuracy, source fidelity and tone as separate criteria.
- Match graders to the task. Prescribing HCPs for clinical relevance, market access experts for payer content, promotional review specialists for compliance.
- Grade blind and adjudicate. At least two graders per item, disagreements resolved and agreement reported.
- Set pass thresholds before testing. Weight severe misses, such as omitted risk, more heavily than style issues.
- Rerun on every change. New model version, new label, new claims library or new content set means a new run.
Which metrics matter for each agent?
Use different metrics for different jobs. A single accuracy figure hides the failures that matter.
| Agent | Key failure | Primary metric | Who grades |
|---|---|---|---|
| Conversational HCP agent | Off-label or unbalanced answer | Severe-error rate per 100 answers | Promotional review specialists, HCPs |
| Content and MLR agent | Missed overclaim | Recall on seeded violations | MLR reviewers |
| Call report agent | Missed compliance flag or lost follow-up | Flag recall, field accuracy | Field leaders, compliance |
| Pre-call planning agent | Talking points that miss how prescribers decide | Expert relevance rating | Prescribing HCPs by specialty |
| Insight and planning agent | Wrong market read | Agreement with expert analysis | Market access and commercial analysts |
For MLR agents, recall matters more than precision. A pre-check that misses an overstated claim does more damage than one that flags too much. Seed known violations into the test set so you can measure what the agent catches.
What should you ask a commercial AI vendor?
Ask these before signing, and ask for the evidence, not the summary:
1. Which agent was each accuracy figure measured on, and with what test set?
2. Who graded the outputs, and what were their credentials?
3. How does the agent behave when the approved content does not answer the question?
4. Can we run our own private evaluation set before rollout and after each update?
5. How are severe errors defined, and what is the rate per 100 outputs?
6. What audit trail exists for each answer and each MLR flag?
A vendor that cannot answer the first two is asking you to trust a number you cannot check.
How Acumen helps
We build the evaluation and training data that sits under commercial AI. Our pharma commercial AI data service supplies HCP objection sets, payer and access scenarios, rubric-graded content evaluation and preference data, all from verified HCPs, market access experts and promotional review specialists. Every item is reviewed and adjudicated.
You can use our data to test a vendor's agent, to tune your own, or both. For the patient-facing and medical information side, see our guide on AI data for medical affairs.
FAQ
What is agentic AI in pharma commercial?
It is AI that completes commercial tasks with some autonomy rather than only answering prompts. Common examples include pre-call planning agents, call report agents, conversational agents on HCP channels, content and MLR pre-check agents, and insight agents that combine sales, CRM and prescription data. Each one drafts, recommends or answers in a regulated setting.
Has FDA issued guidance on AI in drug promotion?
No. A former OPDP project manager said at a RAPS conference in March 2026 that there is no agency guideline on AI in advertising, so companies must infer FDA's thinking. The existing rules on promotional content still apply to anything an agent produces, including fair balance, on-label claims and accurate presentation of data.
How do you test an AI agent for off-label risk?
Build a private test set from your label and claims library. Include realistic HCP questions, off-label requests, pipeline questions and comparative claims. Have promotional review specialists and HCPs grade each answer blind against a rubric, and track the severe-error rate per 100 answers. Seed known violations to measure what the agent misses.
What metrics should we use for an MLR review agent?
Prioritize recall on seeded violations, meaning the share of known overclaims, missing risk statements and indication errors the agent catches. A tool that misses an overstated claim does more harm than one that flags too much. Also track grader agreement, false-flag rate and how often reviewers override the agent.
Are vendor accuracy claims for commercial AI reliable?
Treat them as a starting point. Published figures, such as IQVIA's 97% production accuracy or Veeva's 7x lift from conversational AI, are vendor-reported and usually lack test-set and grader details. Ask which agent was measured, on what cases, by whom, and whether you can run your own private evaluation.
Who should grade commercial AI outputs?
Match the grader to the task. Prescribing HCPs judge clinical relevance and objection handling. Market access and payer experts judge value stories and access content. Promotional review specialists judge fair balance and on-label claims. Use at least two graders per item, resolve disagreements by adjudication and report agreement.